Cap/Iri Plus Cetuximab Compared to Cap/ox Plus Cetuximab in Patients With Metastatic Colorectal Cancer.
A randomized phase II-study to evaluate the safety and efficacy of capecitabine plus irinotecan plus cetuximab compared to capecitabine plus oxaliplatin plus cetuximab in first-line treatment of patients with metastatic colorectal cancer.
Metastatic Colorectal Cancer
DRUG: capecitabine|DRUG: irinotecan|DRUG: oxaliplatin|DRUG: cetuximab
Objective response rate (CR+PR)
Time to progression.|Disease control rate (CR+PR+SD).|Safety profile.|Grade 3/4- toxicities.
A randomized phase II-study to evaluate the safety and efficacy of capecitabine plus irinotecan plus cetuximab compared to capecitabine plus oxaliplatin plus cetuximab in first-line treatment of patients with metastatic colorectal cancer.